LIVE FROM THE DATABASETRANSACTIONS 362,430COMPANIES 5,763LATEST TRADE Oct 16UPDATED Oct 17, 12:31 AM
NVCTCIK 0001875558

Nuvectis Pharma, Inc.

12 transactions by 9 insiders, from November 5, 2025 to August 3, 2026.

Transactions
129 insiders
Bought · P
$1.2Mopen market
Sold · S
Nonenobody sold on the open market
Net
+$1.2Mnet buying

Officers and directors

People inside the company. What they do with their own shares is the reason this data exists.

InsiderTradesPlannedBoughtSold
Ron BentsurCEO3—$279K—
Michael J. CarsonPres2———
Kenneth HobermanDir1———
Matthew L. KaplanDir1———
Shay ShemeshChief1———
Enrique PoradosuChief1———
Juan SanchezDir1———
James F. Oliviero IIIDir1———

Large holders and funds

Holders above 10%, often funds. They file the same form, but they trade for portfolio reasons, not because of what they know.

InsiderTradesPlannedBoughtSold
Marlio Charles Mosseri10%1—$916K—

All transactions

12 in total, newest filings first.

InsiderDateCodeSharesPriceValue
Michael J. CarsonPresAug 3A30,000$0.00—
Marlio Charles Mosseri10%Jun 30P50,000$18.32$916K
Ron BentsurCEOJun 30P12,500$20.00$250K
James F. Oliviero IIIDirJun 11A35,000$0.00—
Juan SanchezDirJun 11A35,000$0.00—
Matthew L. KaplanDirJun 11A35,000$0.00—
Kenneth HobermanDirJun 11A35,000$0.00—
Shay ShemeshChiefJan 6A150,000$0.00—
Enrique PoradosuChiefJan 6A150,000$0.00—
Michael J. CarsonPresJan 6A61,200$0.00—
Ron BentsurCEOJan 6A150,000$0.00—
Ron BentsurCEONov 5P5,000$5.72$29K